Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Novartis; Teva Neuroscience; Actelion; Sanofi-Aventis; Acorda; Questcor; Roche, Genentech; Celgene; Johnson & Johnson; Revalesio; Coronado Bioscience, Genzyme, MedImmune; Bristol-Myers Squibb, Xenoport, Receptos; Forward Pharma
Most, if not all, consulting activity and scientific boards listed above and below involved travel that was either paid for directly or reimbursed.
Biogen Idec & Teva Neuroscience provide study drug for an NIH sponsored clinical trial that I am the PI of. Also, Acorda Therapeutics, Inc.; Biogen Idec; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.; Genzyme; Sanofi; Celgene; NMSS
1) National Multiple Sclerosis Society- PI, 2008-13 2) National Multiple Sclerosis Society- PI, 2014-2019
(1) Bayer Health Care (2) Coronado Biosciences Inc (3)Eli Lilly 7 Company (4) EMD Serono (5) Genentech (6) F. Hoffmann-LaRoche (7) Ironwood Pharmaceuticals Inc (8) ISIS Pharmaceuticals Inc (9) MedImmune Inc (10) Novartis Pharmaceuticals Corporation (11) Opexa Therapeutics (12) sanofi-aventis (13) SK Biopharmaceuticals (14) Synthon Pharmaceuticals Inc (15) Teva Pharmaceuticals Industries (16) Observatoire Fran�ais de la Scl�rosis en Plaques
Multiple Sclerosis: A Guide for the Newly Diagnosed (first, second and third editions), Demos Medical Publishing LLC, 1996-2013
European Committee for Treatment and Research in Multiple Sclerosis (2) National Multiple Sclerosis Society
EMD Serono 1/23/2014, Consulting meeting, $4620 Genentech 4/5/2014, Consulting meeting, $3000 Genzyme/Sanofi 10/24/2013, Consulting meeting, $4985 Innate Immunotherapeutics 1/16/14, Consulting meeting, $2800 Novartis 5/6/13, Steering Committee teleconference, $410 5/22/13, Steering Committee teleconference, $410 6/5/13, Steering Committee teleconference, $410 7/17/13, Steering Committee teleconference, $410 10/3/13, Steering Committee teleconference, $410 Vaccinex 11/3/2013, Consulting meeting, $4000
Cambridge University Press, JA Cohen and RA Rudick, eds, Multiple Sclerosis Therapeutics, 4th edition, 2011
Research support paid to my institution from Biogen Idec, Genzyme, Novartis, Receptos, Synthon, Teva, and Vaccinex
Department of Defense, PR093324, PI, 2010-14 NIH, 1 RO1 NS074787, 2011-4
National MS Society, PP1752, PI, 06/2012-11/2013 Consortium of MS Centers, FWA00005367, PI, 12/2012-11/2013
Participation of Data and Safety Monitoring Committees: Apotek; Biogen-Idec; Cleveland Clinic; Glaxo Smith Klein Pharmaceuticals; Gilead Pharmaceuticals; Modigenetech/Prolor; Merck/Ono Pharmaceuticals; Merck; Neuren; PCT Bio; Revalesio; Sanofi-Aventis; Teva; Vivus; NHLBI (Protocol Review Committee); NINDS; NMSS; NICHD (OPRU oversight committee);
(1) Consortium of MS Centers, speaker honoraria; (2) Genzyme - consulting fees (3) Teva, Speaker honoraria (4) Icahn School of Medicine - grand rounds honoraria
(1) Multiple Sclerosis, Editorial Board, 2010-present (2) JASN, 2013- present, statistical consulting reviewer
Consulting, Speaking fees & Advisory Boards: Alexion; Allozyne; Bayer; Celgene; Coronado Biosciences; Consortium of MS Centers (grant); Diogenix; Immunotherapeutics Klein-Buendel Incorporated; Medimmune; Merck Novartis; Nuron Biotech; Receptos; Spiniflex Pharmaceuticals; Teva pharmaceuticals
(1) NINDS Grant with Multiple Sclerosis as the patient population (2) NARCOMS MS Patient Registry
No direct grants, but work on studies funded to the Consortium of MS Centers subcontracted for analysis of NARCOMS Registry.
U01 NS 042685 (Cutter) 09/23/2005 � 08/31/2015 NIH/NINDS Thymectomy Plus Prednisone vs. Prednisone Alone in NonThymomatous Myasthenia Gravis This multinational clinical trial aims to assess the utility of thymectomy in treating nonthymomatous Myasthenia Gravis patients comparing surgery plus medications versus medications alone. U01 NS 45719 (Lublin) 09/30/2003 � 11/30/2013 NIH/NINDS A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis. The purpose of this project is to assess the impact of combination therapy in the treatment of RRMS. P30 DK 079337 (Agarwal) 09/01/2008 � 07/31/2013 NIH/NIDDK UAB/UCSD O�Brien Core Center for Acute Kidney Injury Research The major objective of this grant is to provide state-of-the-art core resources to address experimental questions for the advancement of AKI research P30-AI 027767 (Saag) 03/01/2009 � 02/28/2014 NIH/NIAID UAB Center for Aids Research is organized as a partnership between the University of Alabama at Birmingham and the Southern Research Institute. The primary purpose of this partnership is to generate interdisciplinary AIDS research efforts. This Center is responsible for planning, evaluating, managing and documenting a broad array of research activities within two institutions. Particular emphasis is placed upon linking clinical and basic science through the use of shared facilities and to translate as quickly as possible fundamental knowledge about AIDS and its related disorders into clinical treatment and prevention programs. No number assigned (Mark) 10/01/2009 � 09/30/2013 National Multiple Sclerosis Society Rehabilitating Extremity Use after Multiple Sclerosis This project compares CI therapy and complementary and alternative medicine treatments to determine their changes in the extent of more-affected arm use in the life setting and maximal movement ability in the laboratory for individuals with multiple sclerosis. R01 HD 064729 (Tita) 04/01/2010 � 03/31/2014 NIH/NICHD Caesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) Trial A multicenter randomized trial to determine the efficacy and safety of a modified (extended-spectrum) antibiotic prophylaxis strategy at cesarean delivery to reduce surgical site infections. UL1 RR 02577 (Kimberly) 05/19/2008 � 04/30/2013 NIH/NCRR UAB Center for Clinical & Translational Science (CCTS) The major goal of this Medicare United with Simple Clinical trials Expanded network (MUSCLE) is to conduct comparative effectiveness research by developing a �network of networks� for conducting pragmatic trials of therapeutics for chronic musculoskeletal diseases. R01 AG 021927 (Marson) 07/01/2010 � 06/30/2015 NIH/NIA Functional Change in Mild Cognitive Impairment (COINS) This R01 project investigates longitudinal change in higher order functional abilities in patients with MCI, and develops predictor models for clinical progression and conversion from MCI to dementia. U01 HL 102235 (Kinsella/Cutter) 09/07/2010 � 06/30/2013 NIH/NHLBI Phase II Trial of Sildenafil in Newborns with Persistent Pulmonary Hypertension This Phase II, multi-center, randomized, double-blind, placebo-controlled trial pursues the hypothesis that IV sildenafil will acutely reduce pulmonary artery pressure and improve oxygenation in near-term and term infants with PPHN, thus reducing the need for rescue therapy iNO and/orECMO. P30 DK 074038 (Yoder) 09/30/2010 � 06/30/2015 NIH/NIDDK Hepato/Renal Fibrocystic Diseases Core Center. The University of Alabama at Birmingham Recessive Polycystic Kidney Disease Core Center (UAB RPKDCC) has established a NIDDK-funded, interdisciplinary center of excellence in PKD-related research, with specific emphasis on recessive PKD. Among the five Cores, the UAB RPKDCC includes the ARPKD Clinical and Genetic Resource, a Core resource designed to develop a unique set of clinical, genetic, and educational resources for ARPKD. The Core has three primary objectives: (1) to extend the observational study of ARPKD initiated by the North American ARPKD Database; (2) to provide a mechanism for genetic evaluation of patients with both classic ARPKD and unusual phenotypes of recessive PKD; and (3) to develop educational tools for physicians and patients regarding the natural history, cause, development and effects of the disease, genetic testing, and clinical trials applicable to ARPKD. R01 AG 037561 (Schneider) 04/01/2011 � 03/31/2014 NIH/NIA Synthesis of Longer-Term Alzheimer Disease Studies in Order to Model and Improve Clinical Trials Methods and Outcomes: Alzheimer Disease Clinical The results of this research will have a broad and lasting impact on trial designs for Alzheimer disease, mild cognitive impairment, and neurodegenerative disorders, and trials in which cognitive improvement is a targeted outcome. It will address important issues in the assumptions underlying the design decisions. This will lead to better understanding and improvement in the methods for future clinical trials and improve the likelihood for identifying effective treatments, as well as identifying ineffective treatments earlier in development. No number assigned (Cutter) 01/01/2004 � 12/31/2012 Consortium of MS Centers (CMSC) North American Research Consortium on Multiple Sclerosis (NARCOMS) The goals of this project are to facilitate a confidential way for patients to supply valuable information to researchers about their course of disease that may lead to more effective treatments and care for people living with MS, while reducing the time and cost of conducting studies; provide a worldwide research resource for people living with multiple sclerosis so they can provide information about themselves and their course of disease; and develop new collaborations between researchers, patients, and healthcare providers. UAB provides programming and analytic support for the NARCOMS registry. BAA-NIAID-DMID-NIHAI2010101 (Gnann/Kimberlin) 10/01/2011 � 09/30/2016 NIH/NIAID These contracts are to accomplish coordinating of various clinical trials with titles listed below: Safety Tolerability and Pharmacokinetics of CMX-001 in Renal Transplant Recipients with BKV Viremia: A Phase IIA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study A Pharmacokinetic/Pharmacodynamic and Resistance Evaluation of Intravenous Ganciclovir in Premature Infants Adaptive Sequential Study Evaluating Prevention of Neonatal HSV: Detection of Maternal Shedding at Delivery Followed by Preemptive Antiviral Therapy in Exposed Neonates A Phase II 6 Weeks Oral Valganciclovir versus Placebo in Infants with Congenital CMV Infection and Hearing Loss 1U34AR062891-01 (Saag) 04/01/2012 � 03/31/2014 NIH/NIAMS Planning Grant for the Active ComparaTor Osteoporosis Large Simple Trial (ATLAST) The overall goals of this project are to collaborate with an advisory group of national osteoporosis, clinical trial, and community research experts to: (1) finalize the study protocol with respect to the study population, recruitment plan, primary and secondary outcomes, data collection/analysis plan; (2) develop a manual of procedures; and (3) develop effective linkages to Medicare data for long-term surveillance of participants.
(1) Consortium of MS Centers (2) Myasthenia Gravis Foundation of America, grant for MG Registry
Pythagoras, Inc. Sub S Corporation - President.
Scientific advisory boards for Biogen Idec, Merck Serono, Novartis, Genmab, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline; has been on steering committees or independent data monitoring boards in clinical trials sponsored by Merck Serono, Genmab, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, and Bayer Schering.
Speaker honoraria from Biogen Idec, Merck Serono, Teva Pharmaceutical Industries Ltd., Bayer Schering, sanofi-aventis, Genzyme, and Novartis.
Previous Editor-in-Chief European Journal of Neurology, Editorial Board: European Journal of Neurology, Therapeutic Advances in Neurological Disorders, Multiple Sclerosis Journal
Honoraria for lecturing from Biogen Idec, Merck Serono, TEVA, and Novartis
The department of Neurology, Rigshospitalet have received unrestricted research grant or compensation for participation in pharmaceutical company sponsored clinical trials from Biogen Idec, Bayer Schering, Merck Serono, TEVA, Sanofi-aventis, Novartis,RoFAR, Roche, and Genzyme
Danish Multiple Sclerosis Society, Danish Medical Research Council, and European Union Sixth Framework Programme: Life Sciences, Genomics and Biotechnology for Health.
(1) Eisai Ltd, Chair of the Advisory Committee (Clinical Neuroscience)2010-March 2013, honorarium to UCL; (2) Chair of the Eisai-UCL Joint Steering Committee for Neuroscience April 2013 to date, honorarium to UCL (3) Imanova, Board member, no compensation; (4) Genzyme, member European Advisory Board (Teriflunomide, Alemtuzumab), June 2013, honorarium and support for travel; International Progressive MS Alliance Scientific Advisory Board
(1) Serono Symposia International Foundation, Invited lectures,honoraria and support for travel; 2) Novartis, Invited lecturer, honorarium and support for travel; (3) Teva, Invited lecturer, honorarium; (4) Remedica, invited lecturer, honorarium and support for travel.
(1) Multiple Sclerosis Journal,Editor-in-Chief, 2006 to date,honorarium (2) Lancet Neurology,Editorial Advisory Board, 2007 to date, free subscription
(1) Development Foundation, Brain Appeal, National Hospital for Neurology and Neurosurgery, Queen Square, London, trustee, no remuneration. (2) National Institute for Health Research, Senior Investigator, honorarium. (3) Dean, UCL Faculty of Brain Sciences, UCL employee. (4) Multiple Sclerosis International Federation (MSIF), Board member and Chair of the International Medical and Scientific Board, no remuneration, support for travel. (5) National Multiple Sclerosis Society, member, Research Programs Advisory Committee,member, no remuneration, support for travel. (6) The Worshipful Company of Pewterers, trustee, no remuneration.
(1) Eisai Inc. to support PhD students at Leonard Wolfson Experimental Neuroscience Centre,Queen Square, London 2012-2017;
(1) NIHR Comprehensive Biomedical Research Centre, co-applicant, New Initiative ref 20, 1/1/2009-31/12/2012; (2) NIHR, Senior Investigator, 2008-2016
(1) Medical Research Council, grant ref MC_PC_12024, 2012-2014; (2) The Wolfson Foundation, grant ref 18575, 2012-2017; (3) Wellcome Trust, grant ref 097815/Z/11/Z, 2012-2013;grant ref 099557/Z/12/A; (4) Multiple Sclerosis Society of GB, award 984,2013-2018; SRH Holding, project 2012-910001, 2012-2014
Compensation for service on steering committees or data monitoring boards for Novartis Pharmaceuticals, Roche, Sanofi, and Teva Pharmaceuticals.
(1) Honoraria were provided from ACTRIMS, the Consortium of MS Centers, Medscape CME, Prime, Serono Symposia International Foundation and Wayne State University. (2) Honoraria were provided from Teva and Teva Neuroscience
(1) Multiple Sclerosis Journal, Sage, Editorial Board, 1994 - present (2) Multiple Sclerosis and Related Diseases, Elsevier, Section Editor, 2011 - present
Reimbursement for services as consultant to AbbVie, Alkermes, Athersys, Inc., Bayer HealthCare, Celgene, EMD Serono, Genentech, Genzyme, Novartis, Roche, Jansen RND, Teva and Teva Neurosciences, and XenoPort.
(1) National Institutes of Health, 2 U01 NS045719-06 (PI of the subcontract to UTHSCH for image analysis), 2002 - 2014 (2) National Institutes of Health, 2RO1-EB002095-06A1 (Co-investigator), 2002 - 2012
(1) National Multiple Sclerosis Society RC 1019-A-5, 2010 - 2012
(1) Royalties are received for monoclonal antibodies out-licensed through the University of Texas Health Science Center at Houston to Millipore (Chemicon International) Corporation since 1993.
I have received speaker's honoraria or travel support to speak at sponsored meetings from Biogen-IDEC, Merck-Serono, Teva Neuroscience and Bayer.
I serve on the Editorial Board for Neurology. I receive no financial remuneration. I also serve on the Editorial Board for a new journal, Multiple Sclerosis and Related Disorders. I receive compensation for this work .
Multiple Sclerosis Society of Canada Multiple Sclerosis Scientific Research Foundation
Scientific consultant to Bayer-Schering, Sanofi- Aventis, Synthon, Novartis, Biogen-Idec, Merck-Serono, Synthon, GE Medical systems, Roche, Janssen, TEVA, Genzyme
Editorial board member for Brain, Eur Radiol, Multiple Sclerosis Journal, Neuroradiology, Radiology, Neurology
Consultant for Sanofi-Aventis, Synthon, Janssen, Novartis, Biogen-Idec, GE medical systems, Roche
Serono Symposia speaker , 2010 and 2011 Novartis symposium speaker 2009, 2010 and 2011 BioClinica symposium speaker 2010 Bayer-Schering symposium speaker 2010 Medscape CME speaker 2011 and 2012
Dutch foundation for MS Research - centre grant 2010-2014
Role of Kv1.3 as neuroprotective Use of Aldehyde dehydrogenease in CD4 T cells to assess response to cyclophosphamide
1 Biogen immunology studies and glial cell biology study 2. Novartis OCTiMS study (no drug involved)
NIH, NINDS NS R-37 041435 PI 2013-2017 NIH, NINDS R-01 NS082347-01 2013-2018 NIH R21 PI 2012-2014
NMSS Collaborative Center Grant 2012-2017 Nancy Davis Foundation Silverman Foundation
In the last two years, I have received personal compensation as a member of Scientific Advisory Boards from commercial entities: 1) Merck Serono; 2) TEVA; 3) Sanofi-Aventis; 4) Genzyme; 5) Novartis; 6) Actelion; 7) Geneuro
In the last two years, I have received personal compensation for speaking activities from commercial entities: 1) Merck Serono; 2) TEVA; 3) Sanofi-Aventis, 4) Genzyme, 5) Novartis; 6) Serono Symposia International Foundation; 7) Biogen; 8) Bayer; 9) Almirall
In the last two years, I have received personal compensation as a member of Scientific Advisory Boards from commercial entities: 1)Bayer, 2) Merck Serono, 3) TEVA, 4) Sanofi, 5) Genzyme, 6) Novartis 7) Actelion 8) Almirall, 9) Chugai, 10) Receptos, 11) Geneuro
Received travel expenses and/or honoraria for lectures or educational activities not funded by industry. Received travel expenses and/or honoraria for consuting activities funded by industry:1.Acorda:consultant 2.Biogen-Idec:consultant 3. Genzyme-sanofi:consultant 4.Teva: consultant 5.GW Pharma: consultant
1.Acorda:consultant 2.Alexion:consultant 3.Biogen-Idec:consultant 4.Genzyme-sanofi:consultant 5 Mylan:consultant; 6 Novartis:consultant;7 Otsuka:consultant; 8 Teva: consultant; Vaccinex; consultant
1.Acorda:research support;2.Biogen-Idec:research support 3.EMD-Serono:research support;4.Genzyme-sanofi:research support;5. Novartis: research support 6.Teva:research support; 7.Ono:research support;8. Takeda:research support, 2010; 11. Ono Pharmaceuticals 2010-2011; 12. Avanir: research support 2012-2014; 13. Sun Pharma:research support 2012-2014; 14. Roche:research support 2012-2014
1 NYSTEM (State of New York): Human glial progenitor cells delivery in MS Currently Funded Grants/Contracts co- PI $4,418,204.00 03/01/2013 02/28/2017 20.0% The goal of this study is to establish a clinical trial of human glial progenitor cells in secondary progressive multiple sclerosis.
1. Mount Sinai School of Medicine; subcontract from NIH for research support. 2. FUNDING AGENCY Mass Gen Hosp/NeuroNEXT (NINDS) Goodman (Site-PI NAME) Fox (PPI) DATES OF ACTIVE/PENDING AWARD 9/1/13-8/31/18 ANTIC TOTAL COSTS $151,880 PERCENT EFFORT 2% TITLE OF PROJECT (OR SUBPROJECT) A Randomized D-B, P-C Study to Evaluate the Safety, Tolerability & Activity of Ibudilast (MN-66) in Subjects with Progressive Multiple Sclerosis. 3. FUNDING AGENCY John Hopkins University GRANT/CONTRACT NUMBER, (PI NAME) Andrew Goodman, MD DATES OF ACTIVE/PENDING AWARD : : 7/15/2011-3/31/2014 ANTIC TOTAL COSTS $0 PERCENT EFFORT 2% TITLE OF PROJECT (OR SUBPROJECT) A Randomized Controlled Trial of Vitamin D in Multiple Sclerosis 3. UNIV/SUNY Buffalo:Establish NYS Multiple Sclerosis Consortium Currently Funded Grants/Contracts Andrew Goodman $0.00 $67,866.00 03/01/1995 10/31/2014 0% The goal of this study is to develop an ongoing, centralized, uniform database of MS patient information and specimens for member centers.
(1)Multiple Sclerosis Journal, (2)Multiple Sclerosis and Related Disorders (3)Journal of Neurology
(1)Actelion, (2)Advancell, (3)Allozyne, (4)BaroFold, (5) Bayer Health Care Pharmaceuticals, (6)Bayer Schering Pharma, (7)Bayhill, (8)Biogen Idec, (9)BioMarin, (10)CLC Behring, (11)Elan, (12)Genmab, (13)Genmark, (14)GeNeuro SA, (15)GlaxoSmithKline, (16)Lilly, (17)Merck Serono, (18) MediciNova, (19)Novartis, (20)Novonordisk, (21) Peptimmune, (22)Sanofi-aventis, (23)Santhera, (24)Roche, (25)Teva, (26)UCB, (27)Wyeth I have also lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis. In many cases these talks have been sponsored by non-restricted educational grants from one or another of the above listed companies. Honoraria and other payments for all these activities have been exclusively used for funding of research of my department. Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by non-restricted grants from one or more of these companies.
Research support by the Swiss National Research Foundation and the European Union
The Swiss MS Society,the Gianni Rubatto Foundation (Zurich)and Novartis and Roche Research Foundations.
Questcor Pharmaceuticals - Advisory board Genzyme/Senofi-Aventis - Advisory board
Acorda Pharmaceuticals - Speaker Honoraria Biogen-Idec - Speaker Honroaria EMD-Serono/Pfizer - Speaker Honoraria Genzyme/Senofi-Aventis - Speaker Honoraria Novartis - Speaker Honoraria Teva - Speaker Honoraria
Journal of Neurological Disorders & Stroke - Editor, 2013 Journal of Neurophysiology and Neurological Disorders - Editor, 2013
Acorda Pharmaceuticals, Biogen-Idec, EMD-Serono/Pfizer, Genzyme/Senofi-Aventis, Novartis, Teva
Teva Pharmaceuticals; St�ve (PI); 10/1/12-12/30/13; Co-Principal Investigator Sanofi-Aventis;Protocol EFC6260; Wolinsky (PI); 10/01/07-03/31/16; Sub-investigator
National Institutes of Health: R01 1R01NS078244-01A1; Narayana (PI); 9/1/2012-5/31/2017; Sub-investigator National Institutes of Health: U01 NS045719-01A1; Lublin (PI); 9/30/03-11/30/12; Sub-investigator
Genzyme/Sanofi-aventis, Biogen Idec, GlaxoSmithKline, EMD Serono, Teva Neuroscience; Merck Serono, Novartis, ONO, Acorda, Nuron Biotech, Questcor
Travel to advisory board meetings for Genzyme/sanofi aventis, Biogen Idec, EMD Serono, Novartis, Acorda
Continuum (AAN) received fees as editor 2003-2012; Continuum Audio (AAN) received fees as editor 2012-present
Genzyme/Sanofi-aventis, Biogen Idec, GlaxoSmithKline, EMD Serono, Teva Neuroscience; Merck Serono, Novartis, ONO, Acorda, Caremark(Accordant Health Services)
Acorda, Novartis, Roche, Questcor, Genzyme/Sanofi-aventis BiogenIdec
(1) Novartis, (2) Teva Pharmaceutical, (3)Merck Serono, (4) Biogen, (5) Bayer Schering Pharma, (6) GSK, (7) Almirall, (8) Neurotec Pharma
Travel to scientific meetings: (1) Novartis, (2) Teva Pharmaceutical, (3)Merck Serono, (4) Biogen, (5) Bayer Schering Pharma, (6) GSK, (7) Almirall, (8) Neurotec Pharma
Member of editorial boards: (1) Multiple Sclerosis, (2) Journal of Neurology, (3) The International MS Journal, (4) Revista Neurologia, (5) Therapeutic Advances in Neurological Disorders
(1) Bayer Schering Pharma, (2) Biogen Idec, (3) Merck-Serono, (4) Teva & Sanofi-Aventis, (5) Novartis, (6) Almirall, (7) Lilly
Vice President, Multiple Sclerosis Foundation of Barcelona (FEM)
Novartis Fingolimod Steering Committee--member--2007-present Teriflunomide Steering Committee ( sanofi aventis)--chairman--2006-present Bayer BEYOND study steering committee--chairman--2007-2009 BRAVO (laquinimod) study DMC--chairman--2007-present Genentech advisory board--member Roche advisory board Receptos advisory board Actelion advisory board
1 Biogen Idec-ECTRIMS meeting Dusseldorf--2009--presentations of data from two studies 2 Teva--Meeting in London--advise and present data on safety of MS drugs--2009 3 Advisory board meeting in Montreal 2010 4 Advisory board meeting in Toronto 2013
Biogen Idec consultant 2007-2012 Actelion consultant 2010 Bayer Consultant 2007-2009 EMD Serono Consultant 2009-11 Teva Consultant 2007-2013 Genentech Consultant 2007-2008 Sanofi Genzyme Consultant 2002-2013 Novartis Consultatn 2005-2013 Warburg Pincus Consultant 2009
1 Bayer--study grant support for BEYOND study--2006-8 2 Novartis--study grant support for FREEDOMS, TRANSFORMS and INFORMS study--2006-2012 3 BIOMS--study grant support 2006-9 4 Sanofi Aventis-grant supprot for TEMSO, phase 2 , CIS and nerispirdine studies 5 ROCHE; grant supprot for phase 2 OCRELIZUMAB study 6 Biogen Idec: grant support for ASCEND and JEMS study 7 Roche grant support for OPERA and ORATORIO studies 8 Novartis support for INFORMS study of PPMS
National Scientific and Clinical Advisor to to the MS Society of Canada. 2008-2014(ongoing)
(1) Natural Sciences and Engineering Research Council of Canada, PI, 35+ years (2) Canadian Institutes for Health Research, co-I, 8 years
(1) National Multiple Sclerosis Society, co-I, 5 years (2) Multiple Sclerosis Society of Canada, co-I, 5 years
(1) Consulting, Genzyme (2) Consulting, Novartis (3) Consulting, Biogen Idec
Editorial Board, Lancet Neurology 2008-present Editorial Board, Neurotherapeutics, 2010-present
Multiple Sclerosis Therapeutics, Third Edition, Cohen, JA, Rudick RA (Eds). Informa Healthcare, UK, 2007
Biogen Idec Consultation x 1, 2012 Genzyme Consultation x 2, 2012, 2013 Novartis Consultation x 1, 2013
Biomarkers for the therapeutic response to IFNb. Measuring gene expression before and after IFNb injections in 85 patients (original study sponsored by NIH - PO1NS38667 - current extension of that study sponsored by Genzyme). Innovative Outcomes Assessment in Gilenya Treated MS Patients. Study sponsored by Novartis
NIH - PO1NS38667 (2004-2009)Director, Project 4 NIH - UL1RR024989 (2007-2011)Co-Principal Investigator NIH - KL2RR024990 (2007-2011) Principal Investigator
National Multiple Sclerosis Society, Research Program Advisory Committee American Society for Experimental Neurotherapeutics (Member, Board of Directors) National Multiple Sclerosis Society, National Board of Directors, Member
Two educational lectures for ABM training(TEVA, company) One physician lectures (Genzyme, company)
Demyelinating disorders of the central nervous system in childhood. Cambridge University. 2011
I am site PI for a trial of ocrelizumab in PPMS (Genentech, company)
I am supported by the NIH, National MS Society, the Race to Erase MS
F.D.L., S.C.R., J.A.C., G.R.C., P.S.S., A.J.T., J.S.W., L.J.B., B. Banwell, F.B., P.A.C., M.C., G.C., M.S.F., A.D.G., L.K., B.C.K., C.L., A.E.M., X.M., P.W.O., J.P., C.P., M.P.S., O.S., and C.H.P. are members of the International Advisory Committee on Clinical Trials in Multiple Sclerosis.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the International Advisory Committee on Clinical Trials in Multiple Sclerosis with funds provided by the European Committee for Treatment and Research in Multiple Sclerosis and the National Multiple Sclerosis Society (USA).
This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.